title: Incidence of increased intraocular pressure after subtenon injection of triamcinolone acetonide.
abstract: OBJECTIVE
  To determine the incidence of eyes that have an increase in the intraocular pressure (IOP) after subtenon injections of triamcinolone acetonide (TA).
  
  
  METHODS
  The medical records of 147 patients treated with single or multiple subtenon injections of TA (10 mg) were reviewed. The incidence of an IOP elevation (ΔIOP) ≥5 mmHg or an IOP of >21 mmHg was determined. The peak ΔIOP, defined as the difference in the IOP at the peak to the baseline IOP, was also evaluated. Multivariate analyses were used to evaluate the relation between the IOP elevation and the age, gender, refractive error, and lens status.
  
  
  RESULTS
  A ΔIOP ≥5 mmHg was found in 75 eyes (46%), and an IOP >21 mmHg was found in 48 eyes (30%) after a single injection of TA. The IOP increased within 3 months in 39 eyes (81%) and after 4 months in 9 eyes (19%). The IOP began to increase significantly from 2 weeks up to 5 months (P<0.05) and returned to the baseline IOP in 10 months. The incidence of ΔIOP ≥5 mmHg or an IOP of >21 mmHg after multiple subtenon injections of TA was significantly higher than after a single injection (62%; P=0.027, 47%; P=0.013, respectively). The incidence of IOP >21 mmHg and the peak ΔIOP were significantly related with younger age (P=0.002, P=0.021, Forward stepwise regression analysis). A weak but significant negative correlation was found between the peak ΔIOP and the age (r=-0.216, P=0.006, Pearson's correlation coefficient test), and the peak ΔIOP and the refractive error (r=-0.198; P=0.018).
  
  
  CONCLUSIONS
  Repeated injections of TAs and injection of younger patients or myopic eyes increase the incidence of an IOP elevation.
authors.affiliation: Department of Ophthalmology, Keio University School of Medicine, Tokyo, Japan.
authors.forename: Ryosuke
authors.initials: R
authors.lastname: Kawamura
authors.forename: Makoto
authors.initials: M
authors.lastname: Inoue
authors.forename: Hajime
authors.initials: H
authors.lastname: Shinoda
authors.forename: Kei
authors.initials: K
authors.lastname: Shinoda
authors.forename: Yuji
authors.initials: Y
authors.lastname: Itoh
authors.forename: Susumu
authors.initials: S
authors.lastname: Ishida
authors.forename: Kazuo
authors.initials: K
authors.lastname: Tsubota
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D016903:Drug Monitoring; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D015994:Incidence; D056965:Injections, Intraocular; D007429:Intraocular Pressure / Q000187:drug effects*; D007564:Japan / Q000453:epidemiology; D008297:Male; D008499:Medical Records; D008875:Middle Aged; D009798:Ocular Hypertension / Q000139:chemically induced* / Q000453:epidemiology; D012030:Refractive Errors / Q000150:complications / Q000503:physiopathology; D012164:Retinal Diseases / Q000150:complications / Q000188:drug therapy; D012189:Retrospective Studies; D058475:Tenon Capsule; D013997:Time Factors; D014222:Triamcinolone Acetonide / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide